Literature DB >> 11871762

Five days of ceftriaxone to treat spontaneous bacterial peritonitis in cirrhotic patients.

AlexVianeyCallado França1, Helena Maria Giordano, Tiago Sevá-Pereira, Elza Cotrim Soares.   

Abstract

BACKGROUND: The aim of this study was to determine whether a short course of ceftriaxone was sufficient to cure spontaneous bacterial peritonitis (SBP) in cirrhotic patients.
METHODS: We studied 33 cirrhotic patients with SBP. All of them were treated with ceftriaxone, 1.0 g IV, every 12 h for 5 days. Twenty-one variables were recorded to evaluate their relationship to the resolution of SBP.
RESULTS: The mean age of the patients was 45 years. Twenty-three were males and 10 females. The etiology of cirrhosis was alcoholic in 42% of the patients, and 82% of the patients belonged to Child-Pugh Class C. Hepatic encephalopathy was present in 39% of the patients. The most frequent organism causing SBP was Escherichia coli (60%). Resolution of SBP on day 5 of treatment was achieved in 73% of the patients. Total resolution of SBP after prolonged therapy with ceftriaxone or another agent. selected according to antibiotic susceptibility, was achieved in 94% of the patients. Hospital mortality was 12%. Multivariate analysis showed no factor that was significantly related to the resolution of SBP, but univariate analysis showed that renal impairment and positive culture tended to be related.
CONCLUSIONS: A short course (5 days) of ceftriaxone is useful therapy for SBP. If the polymorphonuclear differential count in ascitic fluid is less than 250 cells/mm3 on day 5 of treatment, the antibiotic can be discontinued.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11871762     DOI: 10.1007/s005350200006

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  9 in total

1.  Spontaneous bacterial peritonitis: a review of treatment options.

Authors:  Cesar Alaniz; Randolph E Regal
Journal:  P T       Date:  2009-04

2.  Spontaneous bacterial peritonitis: a severe complication of liver cirrhosis.

Authors:  Jan Lata; Oldrich Stiburek; Marcela Kopacova
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

3.  Evidence of Significant Ceftriaxone and Quinolone Resistance in Cirrhotics with Spontaneous Bacterial Peritonitis.

Authors:  Eric Ardolino; Susan S Wang; Vilas R Patwardhan
Journal:  Dig Dis Sci       Date:  2019-02-14       Impact factor: 3.199

Review 4.  Spontaneous bacterial peritonitis.

Authors:  Anastasios Koulaouzidis; Shivaram Bhat; Athar A Saeed
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

Review 5.  Antibiotics for spontaneous bacterial peritonitis in cirrhotic patients.

Authors:  Norberto C Chavez-Tapia; Karla Soares-Weiser; Mayer Brezis; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

Review 6.  KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-07-09

7.  Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case-control study.

Authors:  Kyoung-Ho Song; Jae Hyun Jeon; Wan Beom Park; Sang-Won Park; Hong Bin Kim; Myoung-don Oh; Hyo-Suk Lee; Nam Joong Kim; Kang Won Choe
Journal:  BMC Infect Dis       Date:  2009-04-12       Impact factor: 3.090

8.  A case of cell-free and concentrated ascites reinfusion therapy effective for refractory ascites in spontaneous bacterial peritonitis in a renal transplant patient.

Authors:  Atsuhiro Maeda; Kazuhito Takeda; Kazuhiko Tsuruya; Shuuhei Miura; Jirou Toyonaga; Satsuki Nakashita; Masahide Furushou; Hideyuki Mukai; Yoshiharu Mutou; Tomo Komaki; Keita Takae; Chikao Yasunaga
Journal:  Case Rep Nephrol Urol       Date:  2012-09-24

9.  A retrospective analysis of cases of Spontaneous Bacterial Peritonitis in cirrhosis patients.

Authors:  Phillip Pasquale Santoiemma; Omar Dakwar; Michael Peter Angarone
Journal:  PLoS One       Date:  2020-09-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.